2cureX

2cureX Tangible Book Value per Share

Delisted·Sep 2, 2026

The Tangible Book Value per Share of 2cureX (2CUREX.ST) as of Oct 16, 2026 is 0.20 SEK. In the previous year, Tangible Book Value per Share was 0.48 SEK — a change of -57.78% (lower).

Tangible Book Value per Share

0.20SEK

YoY

-57.78%

Last updated:

Tangible Book Value per Share of 2cureX is 2024 0.20 SEK. Tangible Book Value per Share of 2cureX was 2023 0.48 SEK. It decreases by -57.78% lower compared to the previous year.

The 2cureX Tangible Book Value per Share history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Tangible Book Value per Share
Date
Tangible Book Value per Share
Jan 1, 2017
0.81 SEK
Jan 1, 2018
0.54 SEK
Jan 1, 2019
1.12 SEK
Jan 1, 2020
2.35 SEK
Jan 1, 2021
2.96 SEK
Jan 1, 2022
1.71 SEK
Jan 1, 2023
0.48 SEK
Jan 1, 2024
0.20 SEK
The 2cureX Tangible Book Value per Share history
YEARTangible Book Value per ShareYoY
0.20SEK-57.78%
0.48SEK-71.93%
1.71SEK-42.12%
2.96SEK+26.30%
2.35SEK+109.66%
1.12SEK+106.12%
0.54SEK-32.69%
0.81SEK+155.68%
0.32SEK-3.34%
0.33SEK—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

2cureX Stock analysis

What does 2cureX do? 2cureX AB is a healthcare company based in Landskrona, Sweden, listed on the Stockholm Stock Exchange under the ticker 2CUREX.ST. The company went public via an IPO on November 24, 2017. 2cureX AB specializes in research and development of anti-cancer treatments, focusing on diagnostic substances to guide cancer patient treatment decisions. The company's primary product candidate, IndiTreat - CRC, is designed to optimize treatment for colorectal cancer patients. This technology involves creating three-dimensional micro-tumors from patient tumor samples to test various chemotherapies and experimental treatments. 2cureX AB also has additional product candidates in its pipeline, including IndiTreat - OVA for ovarian cancer treatment and IndiTreat - KDN for kidney cancer treatment. The company operates through its subsidiary 2cureX A/S. While the company's website is https://www.2curex.com/, the provided information does not include details about its founding year, key personnel, specific financial figures, or the exact nature of its research methodologies beyond the described product candidates. The company's operations are centered on developing diagnostic tools to personalize cancer treatment approaches. 2cureX is one of the most popular companies on Eulerpool.

Frequently Asked Questions about 2cureX stock

Tangible Book Value per Share of 2cureX is 0.20 SEK in 2024.

Tangible Book Value per Share of 2cureX changed from 0.48 SEK to 0.20 SEK, representing a -57.78% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Tangible Book Value per Share 2cureX since 2006 – with annual values, charts, and detailed analysis.

Tangible book value per share excludes intangible assets and goodwill, providing a more conservative measure of per-share net asset value.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Balance Sheet — 2cureX

Total AssetsCurrent AssetsCash & EquivalentsReceivablesInventoryProperty, Plant & EquipmentGoodwillIntangible AssetsEquityLiabilitiesDebtCurrent LiabilitiesLong-term DebtShort-term DebtRetained EarningsBook Value per ShareTangible Book Value per ShareWorking CapitalInvestmentsAccounts PayableNon-Current AssetsShort-Term InvestmentsLong-Term InvestmentsNet DebtTreasury StockMinority InterestDeferred Tax LiabilitiesNet Tangible AssetsGoodwill/AssetsIntangibles/Assets

All Key Metrics — 2cureX